Clinical Trials Logo
  1. Home
  2. Social Anxiety Disorder
  3. NCT02924610
  4. Details
NCT02924610 Clinical Trial

Brief Intervention to Reduce Fear

Social Anxiety Disorder Clinical Trial

Official title:
Brief Intervention to Reduce Fear

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT02924610
Other study ID # 7293
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received October 3, 2016
Last updated October 4, 2016
Start date October 2016

Study information
Verified date October 2016
Source Research Foundation for Mental Hygiene, Inc.
Contact Danielle Moskow, BA
Phone 6467748013
Email dmoskow@nyspi.columbia.edu
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The study will test the efficacy of propranolol or placebo, administered after retrieval of a previously acquired public speaking fear, in reducing fear and avoidance of public speaking.

Description:

Twenty subjects with Performance-Only type of Social Anxiety Disorder will be enrolled in the study. They will complete baseline assessments of fear and avoidance of public speaking. They will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear activation procedure. Primary outcome assessment will be self-reported fear of public speaking and avoidance behavior in a behavioral avoidance task 2 weeks after the intervention.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 20
Est. completion date
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: Principal Diagnosis of Social Anxiety Disorder, Performance only type; has clinically significant fear of public speaking; physically healthy

Exclusion Criteria: History of other serious psychiatric disorder, current Major Depressive Disorder, women who are pregnant or nursing, current use of psychiatric medication, persons planning to start another treatment during the study period, any significant medical condition that might increase the risk or participation or use of medications that might negatively interact with propranolol.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Related Conditions & MeSH terms

Intervention

Drug:
• propranolol
active treatment
• placebo
inactive pill

Locations
Country Name City State
United States New York State Psychiatric Institute, 1051 Riverside Drive New York New York

Sponsors (1)
Lead Sponsor Collaborator
Research Foundation for Mental Hygiene, Inc.

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Personal Report of Confidence as a Speaker self report measure of fear of public speaking 2 weeks No
Secondary Behavioral Avoidance Task task assessing fear and avoidance of public speaking 2 weeks No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06274112 - Using TMS to Understand Neural Processes of Social Motivation N/A
Completed NCT02554929 - Treatment of Social Anxiety Disorder and Selective Mutism N/A
Completed NCT00684541 - Interpretation Modification Program for Social Phobia N/A
Completed NCT00684320 - Attention Disengagement Training for Social Phobia N/A
Completed NCT03247075 - Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT N/A
Completed NCT02811458 - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders N/A
Withdrawn NCT04622930 - Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD) N/A
Active, not recruiting NCT05018312 - Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety N/A
Completed NCT05858294 - The Safety, Acceptability and Efficacy of Alena N/A
Active, not recruiting NCT05600114 - Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder Phase 2
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Active, not recruiting NCT02592564 - Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder N/A
Recruiting NCT02305537 - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment N/A
Terminated NCT03764644 - Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders N/A
Unknown status NCT01712321 - Study of Vilazodone to Treat Social Anxiety Disorder N/A
Completed NCT01320800 - CBT for Social Anxiety Disorder Delivered by School Counselors Phase 2
Completed NCT00485615 - An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia Phase 2
Completed NCT00773162 - Flushing in Social Anxiety Disorder on Seroquel Phase 3
Completed NCT00872820 - Examining Long-Term Effects and Neural Mediators of Behavioral Treatments for Social Anxiety Disorder N/A
Completed NCT00485888 - Flushing in Social Anxiety Disorder on Cipralex Phase 2